TY - JOUR
T1 - Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)
AU - Pérez-Molina, José A.
AU - Polo, Rosa
AU - López-Aldeguer, José
AU - Lozano, Fernando
AU - Aguirrebengoa, Koldo
AU - Arribas, José Ramón
AU - Boix, Vicente
AU - Berenguer, Juan
AU - Blanco, José Ramón
AU - Domingo, Pere
AU - Estrada, Vicente
AU - Galindo, María José
AU - García, Federico
AU - Gatell, José María
AU - González-García, Juan
AU - Gutiérrez, Félix
AU - Iribarren, José Antonio
AU - Knobel, Hernando
AU - Llibre, Josep María
AU - López-Bernaldo de Quirós, Juan Carlos
AU - López-Cortés, Luis Fernando
AU - Losa, Juan Emilio
AU - Mariño, Ana
AU - Miró, José M.
AU - Montes, María L.
AU - Moreno, Santiago
AU - Negredo, Eugenia
AU - Pérez-Elías, María J.
AU - Podzamczer, Daniel
AU - Portilla, Joaquín
AU - Poveda, Eva
AU - Pulido, Federico
AU - Ribera, Esteban
AU - Rivero, Antonio
AU - Rubio, Rafael
AU - Santos, Jesús
AU - Sanz-Moreno, José
AU - Sanz-Sanz, Jesús
AU - Serrano, Sergio
AU - de la Torre, Javier
AU - Tuset, Montserrat
AU - von Wichman, Miguel A.
AU - Martínez, Esteban
PY - 2019/3/1
Y1 - 2019/3/1
N2 - © 2018 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica This update to the document on antiretroviral therapy (ART) in adults, which has been prepared jointly by GeSIDA and the Spanish National AIDS Plan for the last two decades, supersedes the document published in 2017. 1 The update provides physicians treating HIV-1-infected adults with evidence-based recommendations to guide their therapeutic decisions. The main difference with respect to the previous document concerns recommended initial ART regimens, only three of which are maintained as preferential. All three include dolutegravir or raltegravir, together with emtricitabine/tenofovir alafenamide or abacavir/lamivudine. Other differences concern the section on switching ART in patients with suppressed viral replication, which now includes new two- and three-drug regimens, and the antiretroviral drugs recommended for pregnant women and patients with tuberculosis. A recommendation has also been added for patients who present with acute HIV infection after pre-exposure prophylaxis.
AB - © 2018 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica This update to the document on antiretroviral therapy (ART) in adults, which has been prepared jointly by GeSIDA and the Spanish National AIDS Plan for the last two decades, supersedes the document published in 2017. 1 The update provides physicians treating HIV-1-infected adults with evidence-based recommendations to guide their therapeutic decisions. The main difference with respect to the previous document concerns recommended initial ART regimens, only three of which are maintained as preferential. All three include dolutegravir or raltegravir, together with emtricitabine/tenofovir alafenamide or abacavir/lamivudine. Other differences concern the section on switching ART in patients with suppressed viral replication, which now includes new two- and three-drug regimens, and the antiretroviral drugs recommended for pregnant women and patients with tuberculosis. A recommendation has also been added for patients who present with acute HIV infection after pre-exposure prophylaxis.
KW - AIDS
KW - Antiretroviral therapy
KW - Clinical guidelines
KW - GeSIDA
KW - Human immunodeficiency virus
KW - Recommendations
KW - Spanish National AIDS Plan
UR - https://www.scopus.com/pages/publications/85046878157
U2 - 10.1016/j.eimc.2018.02.010
DO - 10.1016/j.eimc.2018.02.010
M3 - Artículo
C2 - 29759422
AN - SCOPUS:85046878157
SN - 0213-005X
VL - 37
SP - 195
EP - 202
JO - Enfermedades Infecciosas y Microbiologia Clinica
JF - Enfermedades Infecciosas y Microbiologia Clinica
IS - 3
ER -
